# Pizarra — PT-pseudo_e001f4d06517 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e001f4d06517
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 73-year-old male
  - PSA: 4.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 0.21 ng/mL/yr
  - Prior PSA: 3.5 ng/mL
  - Prostate volume: 56.09 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7867544 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.5 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 56 mL. csPCa 0.79.

Vitals: weight 108 kg, height 196 cm, BMI 28.1, BP 133/70 mmHg, HR 65 bpm. Smoking: Current smoker (23 pack-yr).

Chief complaint: Assessment requested for a PSA rise to 4.5 ng/mL alongside a history of a previously positive prostate biopsy.

History: At 73 years of age, this married harbour pilot, currently semi-retired, seeks clinical review due to a PSA elevation to 4.5 ng/mL. He resides independently while maintaining a close bond with his spouse and a long-standing friend who handles administrative tasks. A current smoker with a 23 pack-year history, he denies any unexplained weight loss or altered bowel habits. His daily routine includes light weight-training twice weekly, and he consumes roughly 25 units of alcohol each week. Lower urinary tract symptoms remain minimal, reflected by an IPSS score of 3. No comorbidities exist, and he takes no active medications. An earlier memory clinic screening yielded unremarkable results, and aside from occasional mild knee stiffness managed with over-the-counter analgesics, he reports feeling well. He specifically requested a morning appointment to accommodate public transit.

Physical examination: DRE: The prostate presents symmetrically enlarged, exhibiting a smooth texture and firm consistency without palpable asymmetry or discrete nodules. General inspection shows a well-nourished individual in no acute distress. Lung fields remain clear, and cardiac rhythm is regular at 65 beats per minute. Abdominal palpation yields a soft, non-tender abdomen devoid of masses or organomegaly.

Patient info: harbour pilot (semi-retired); Married; Lives alone.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 25 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 3/35 (mild LUTS).

Recent other appointments: Memory clinic — baseline screening.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.56 +/- 0.20   (95% CI 0.18-0.90)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.13  (few labelled cases resemble this one)
  - 7.4 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=4.5, age=73.0, psad=0.08, dre_ord=0.0, vol=56.09, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's current PSA velocity (0.21 ng/mL/yr) against the prior PSA (3.5 ng/mL) and the recent rise to 4.5 ng/mL. It also did not see the specific findings from the mpMRI report (PI-RADS 4) or the full context of the PSA history/trend, which are crucial for risk stratification.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier decision (0.56 +/- 0.20). This wide interval suggests the input features are highly ambiguous for the model. A failure mode is ignoring the significant PSA velocity (0.21 ng/mL/yr) which indicates a concerning trend, potentially overriding the PI-RADS 4 score. Another failure mode is the prior positive biopsy status; if the prior biopsy was positive, the question "does he have cancer" is fundamentally different from a screening question, which the prior cannot account for.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant clinically significant cancer features (e.g., focal lesions), it would strongly push towards biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the urgency for a biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the prior positive biopsy or any prior risk assessment that influences the current decision.
  <document> laboratory results (full panel) -> This panel might provide context on other markers or comorbidities that influence the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Radiology Division | Tergooi MC | 10 Feb 2025 | Multiparametric MRI of the Prostate

  Clinical Indication:
  Re-assessment following a previously positive biopsy. Presenting PSA stands at 4.5 ng/mL, building on a prior PI-RADS 4 finding.

  FINDINGS:
  The gland measures 56.09 mL overall. T2-weighted sequences highlight a focal hypointense abnormality located in the right mid-gland posterior peripheral zone, spanning approximately 18 mm at its greatest axis. High b-value DWI shows pronounced restricted diffusion with matching low ADC signal. Dynamic contrast-enhanced sequences exhibit early, focal enhancement against the background parenchyma. Extraprostatic extension and seminal vesicle invasion are absent. Neurovascular bundles remain intact. Pelvic lymphadenopathy shows no suspicious features.

  IMPRESSION:
  PI-RADS 4 lesion in the right mid-gland posterior peripheral zone.
  Prostate volume 56.09 mL; PSA density 0.08 ng/mL/mL.
  csPCa predicted probability 0.7867544.

  **psa_trend**
  {"case_id": "PT-pseudo_e001f4d06517", "psa_trend": [{"date": "Feb 2024", "val": 2.7}, {"date": "May 2024", "val": 3.1}, {"date": "Aug 2024", "val": 3.5}, {"date": "Nov 2024", "val": 4.0}, {"date": "Feb 2025", "val": 4.5}]}

  **previous_notes**
  {"case_id": "PT-pseudo_e001f4d06517", "previous_notes": [{"date": "05 Mar 2024", "author": "Dr. P. van Dijk (GP)", "text": "05 Mar 2024 \u2013 GP P. van Dijk: Assessment of established prostate findings. Laboratory results from 28 Feb 2024 placed the PSA at 3.6 ng/mL, remaining within monitored parameters following last year\u2019s positive biopsy. Clinical monitoring continued, with a PSA recheck scheduled for six months later. The patient was instructed to flag any fresh lower urinary tract symptoms."}, {"date": "31 Oct 2024", "author": "Dr. P. van Dijk (GP)", "text": "31 Oct 2024 \u2013 GP P. van Dijk: Standard PSA monitoring recorded a value of 3.5 ng/mL, tracking steadily against the prior quarter. Following the established diagnostic history, laboratory documentation was compiled for the urology clinic visit, with the patient directed to bring the recent test results to the consultation."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_e001f4d06517", "laboratory_results": [{"name": "PSA", "val": "4.5 ng/mL", "date": "11 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.15 ng/mL", "date": "11 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "25%", "date": "11 Feb 2025", "flag": ""}, {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "11 Feb 2025", "flag": ""}, {"name": "WBC", "val": "4.7 x10^9/L", "date": "11 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "295 x10^9/L", "date": "11 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "94 umol/L", "date": "11 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "11 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "8.3 nmol/L", "date": "11 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "90 U/L", "date": "11 Feb 2025", "flag": ""}, {"name": "LDH", "val": "163 U/L", "date": "11 Feb 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 4 lesion in the right mid-gland posterior peripheral zone
  PSA velocity of 0.21 ng/mL/yr (from trend data)
  PSA has risen from 3.5 ng/mL to 4.5 ng/mL in one month.
  Prior biopsy was positive.

  AGAINST sampling this patient now:
  DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  DRE findings: smooth texture and firm consistency without palpable asymmetry or discrete nodules.
  Extraprostatic extension and seminal vesicle invasion are absent (from MRI report).

WHERE THIS LEANS
  The retrieved evidence strongly argues for sampling due to the PI-RADS 4 finding and the concerning PSA velocity, which contradicts the statistical prior's 'discuss' tier by highlighting specific high-risk imaging and trend data.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the presence of a PI-RADS 4 lesion in the right mid-gland posterior peripheral zone and a concerning PSA velocity of 0.21 ng/mL/yr. This finding, combined with the PSA rising from 3.5 ng/mL to 4.5 ng/mL in one month, strongly justifies sampling, despite the prior positive biopsy. The statistical prior suggested a 'discuss' tier, but the retrieved evidence points clearly toward intervention.

Variables that carried weight: bx=noted, age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
